People Background Check
Find People:

Janet M Leeds, Age 67160 Molimo Dr, San Francisco, CA 94127

Get Report
Known as:
Janet Marie Leeds Janet M L Matthews Janet M Matthews Jm Leeds
Related to:
Georgette Y Liebhaber 70

Janet Leeds Phones & Addresses

160 Molimo Dr, San Francisco, CA 94127

Berkeley, CA

Albany, OR

Corvallis, OR

443 Dunsmore Ct, Encinitas, CA 92024

Carlsbad, CA

Cardiff by the Sea, CA

Durham, NC

Campo, CA

San Diego, CA

Show more

Mentions for Janet M Leeds

Janet Leeds resumes & CV records

Resumes

Janet Leeds Photo 24

Executive Director Dmpk And Toxicology

Location:
San Francisco, CA
Industry:
Pharmaceuticals
Work:
Siga Technologies Mar 2009 - Oct 2013
Senior Director of Preclinical Research Portola Pharmaceuticals Mar 2009 - Oct 2013
Executive Director Dmpk and Toxicology Chdi Jul 2005 - Dec 2008
Director of Preclinical Development Independent Consultant Jan 2004 - Jul 2005
Pharmacology and Toxicology Consultant Biota Laboratories Sep 2001 - Dec 2003
Director of Pharmacology Ionis Pharmaceuticals, Inc. Jun 1993 - Sep 2001
Associate Director
Education:
Oregon State University
Doctorates, Doctor of Philosophy, Biochemistry, Biophysics University of Illinois at Urbana - Champaign
Bachelors, Bachelor of Science, Biochemistry, Chemistry
Skills:
Drug Development, Adme, Clinical Development, Cro, Ind, Pharmacology, Drug Discovery, Toxicology, Bioanalysis, Regulatory Submissions, Assay Development, In Vitro, Glp, Clinical Trials, Small Molecules, Pk/Pd, Drug Metabolism, Pharmacokinetics, Lead Change, Sop, Biomarker Discovery, In Vivo, Nda, Biomarkers, Pharmacodynamics, Translational Medicine, Lead Optimization
Certifications:
Diplomate of the American Board of Toxicology
American Board of Toxicology
Janet Leeds Photo 25

Janet Leeds

Publications & IP owners

Us Patents

Method For Quantitating Oligonucleotides

US Patent:
6355438, Mar 12, 2002
Filed:
Nov 10, 2000
Appl. No.:
09/711050
Inventors:
Brenda F. Baker - Carlsbad CA
Zhengrong Yu - Carlsbad CA
Janet M. Leeds - Encinitas CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C12Q 168
US Classification:
435 6, 435 911, 435 912, 536 221, 536 231, 536 243, 536 2433
Abstract:
Methods and processes for quantitating the amount of oligonucleotide in a sample of bodily fluid and/or extract are provided. The methods and processes provided allow for the detection and/or localization of oligonucleotides for therapeutic and/or pharmacokinetic purposes by providing a highly sensitive assay that takes advantage of enzymes which recognize specific nucleic acid conformations and structures.

Nucleotide Mimics And Their Prodrugs

US Patent:
7285658, Oct 23, 2007
Filed:
Feb 28, 2003
Appl. No.:
10/376654
Inventors:
Phillip D. Cook - Fallbrook CA, US
Guangyi Wang - Carlsbad CA, US
Thomas W. Bruice - Carlsbad CA, US
Nicholas A. Boyle - Encinitas CA, US
Janet M. Leeds - Encinitas CA, US
Jennifer L. Brooks - Encinitas CA, US
Marija Prhavc - Encinitas CA, US
Maria Eugenia Ariza - San Marcos CA, US
Patrick C. Fagan - Escondido CA, US
Yi Jin - Carlsbad CA, US
Vivek K. Rajwanshi - Vista CA, US
Kathleen D. Tucker - Escondido CA, US
Assignee:
Biota, Inc. - Carlsbad CA
International Classification:
A61K 31/7072
A61K 31/7076
C07H 19/167
C07H 19/173
C07H 19/19
C07H 19/20
US Classification:
536 262, 536 2622, 536 2626, 514 49, 514 51
Abstract:
The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

Nucleotide Mimics And Their Prodrugs

US Patent:
7598230, Oct 6, 2009
Filed:
Jun 14, 2007
Appl. No.:
11/818990
Inventors:
Phillip D. Cook - Fallbrook CA, US
Guangyi Wang - Carlsbad CA, US
Thomas W. Bruice - Carlsbad CA, US
Nicholas A. Boyle - Encinitas CA, US
Janet M. Leeds - Encinitas CA, US
Jennifer L. Brooks - Encinitas CA, US
Marija Prhavc - Encinitas CA, US
Maria Eugenia Ariza - San Marcos CA, US
Patrick C. Fagan - Escondido CA, US
Yi Jin - Carlsbad CA, US
Vivek K. Rajwanshi - Vista CA, US
Kathleen D. Tucker - Escondido CA, US
Assignee:
Biota Scientific Management Pty Ltd - Notting Hill, Victoria
International Classification:
C07H 19/10
US Classification:
514 51, 514 52, 536 262, 536 268, 536 2851, 536 2853
Abstract:
The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

Nucleotide Mimics And Their Prodrugs

US Patent:
7807653, Oct 5, 2010
Filed:
Jun 14, 2007
Appl. No.:
11/818666
Inventors:
Phillip D. Cook - Fallbrook CA, US
Guangyi Wang - Carlsbad CA, US
Thomas W. Bruice - Carlsbad CA, US
Nicholas A. Boyle - Encinitas CA, US
Janet M. Leeds - Encinitas CA, US
Jennifer L. Brooks - Encinitas CA, US
Marija Prhavc - Encinitas CA, US
Maria Eugenia Ariza - San Marcos CA, US
Patrick C. Fagan - Escondido CA, US
Yi Jin - Carlsbad CA, US
Vivek K. Rajwanshi - Vista CA, US
Kathleen D. Tucker - Escondido CA, US
Assignee:
Biota Scientific Management Pty Ltd - Notting Hill, Victoria
International Classification:
A61K 31/7076
A61K 31/708
C07H 19/20
US Classification:
514 47, 514 48, 536 276, 536 2761, 536 2762, 536 2763, 536 277, 536 278, 536 2781
Abstract:
The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

Nucleoside 5'-Monophosphate Mimics And Their Prodrugs

US Patent:
2004002, Feb 5, 2004
Filed:
Feb 28, 2003
Appl. No.:
10/376949
Inventors:
Phillip Cook - Fallbrook CA, US
Guangyi Wang - Carlsbad CA, US
Thomas Bruice - Carlsbad CA, US
Kandasamy Sakthivel - San Diego CA, US
Kathleen Tucker - Escondido CA, US
Jennifer Brooks - Encinitas CA, US
Janet Leeds - Encinitas CA, US
Maria Ariza - San Marcos CA, US
Patrick Fagan - Escondido CA, US
International Classification:
C07H019/04
A61K031/675
A61K031/7056
US Classification:
514/043000, 514/080000, 536/026100, 548/112000
Abstract:
The present invention relates to novel nucleoside 5′-monophosphate mimics, which contain novel nucleoside bases and phosphate moiety mimics optionally having sugar-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, anticancer, and immunomodulatory agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

Compositions And Their Uses Directed To Huntingtin

US Patent:
2010006, Mar 18, 2010
Filed:
Nov 13, 2009
Appl. No.:
12/618470
Inventors:
Gene Hung - San Diego CA, US
Janet M. Leeds - Encinitas CA, US
C. Frank Bennett - Carlsbad CA, US
Susan M. Freier - San Diego CA, US
Assignee:
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
A61K 31/7088
C07H 21/04
A61P 25/28
US Classification:
514 44 R, 536 231
Abstract:
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.

Fluorescence Based Nuclease Assay

US Patent:
6127124, Oct 3, 2000
Filed:
Jan 20, 1999
Appl. No.:
9/234237
Inventors:
Janet M. Leeds - Encinitas CA
Lendell L. Cummins - San Deigo CA
Assignee:
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
G01N 3300
C12Q 168
C12P 1934
C07H 2104
US Classification:
435 6
Abstract:
Methods for the determination of nuclease stability of an oligomeric compound and its deletion sequences by capillary gel electrophoresis using laser-induced fluorescence detection (LIF CGE) are provided. Fluorescently labeled oligomeric compounds are treated with one or more agents having nuclease activity resulting in an assay mixture of the original oligomeric compound and its deletion sequences. A diluted aliquot taken directly from the assay mixture is analyzed using LIF CGE. Results of the assay yield quantitative concentrations of the oligomeric compound and each of the deletion sequences. In further embodiments, the invention provides methods for determining the relative binding affinity of one or more oligomeric compounds for a substrate having nuclease activity, and methods for determining the nuclease activity of an enzyme.

Compositions And Their Uses Directed To Huntingtin

US Patent:
2021001, Jan 21, 2021
Filed:
Aug 10, 2020
Appl. No.:
16/988862
Inventors:
- Carlsbad CA, US
- New York NY, US
Janet M. Leeds - Encinitas CA, US
Susan M. Freier - San Diego CA, US
International Classification:
C12N 15/113
Abstract:
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.

Possible Relatives

Deanna M Leeds  Edward L Leeds  Eric J Leeds  Adam D Leeds  James Leeds  Jeff S Leeds  Jeffrey R Leeds  Janet S Last  Janet L Johnston  Janet L Stanford 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.